| NCT ID | NCT07193849 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | King Abdullah Medical City |
| Condition | Pressure Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 76 participants |
| Start Date | 2023-12-31 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 76 participants in total. It began in 2023-12-31 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
randomize control trial to evaluate the efficacy of using zinc oxide versus moist exposed wound ointment in treatment of second stage pressure ulcer.
Eligibility Criteria
Inclusion Criteria: * Willing to participate. * KAMC cases in medical ward, neuroscience ward, and intensive care unit. * Newly cases diagnosed with second stage pressure ulcer according to the European pressure ulcer advisory panel/national pressure ulcer advisory panel (NPUAP) guidelines. Exclusion Criteria: * Not consenting to participate * Patients with suspected hypersensitivity reactions to any of the topical formulation's ingredients. * Either a category III or IV pressure ulcer. * Evidence of deep tissue injury (exudative drainage, purple or maroon localized area of discolored intact skin or blood-filled blister due to pressure damage). * Signs of wound infection (pus draining from the ulcer, a foul-smelling odour, tenderness, heat and increased redness in the surrounding skin and fever). * Patients who undertaking other therapies that could affect healing, such as corticosteroids, radiation therapy, or chemotherapy for cancer. * Heavy smoking (more than 20 cigarettes a day). * Concomitant chronic disease (e.g., diabetes mellitus or frank vascular disease such as Buerger's disease). * Patients who unable to continue the study because of death, discharge, or change in the care setting.
Contact & Investigator
Dr. Ebtisam AbdElatif Ebrahim, Master degree of science in nu
PRINCIPAL INVESTIGATOR
King Abdullah Medical City in Holy Capital
Frequently Asked Questions
Who can join the NCT07193849 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pressure Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07193849 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07193849 currently recruiting?
Yes, NCT07193849 is actively recruiting participants. Contact the research team at Almwlld.W@kamc.med.sa for enrollment information.
Where is the NCT07193849 trial being conducted?
This trial is being conducted at Mecca, Saudi Arabia, Mecca, Saudi Arabia.
Who is sponsoring the NCT07193849 clinical trial?
NCT07193849 is sponsored by King Abdullah Medical City. The principal investigator is Dr. Ebtisam AbdElatif Ebrahim, Master degree of science in nu at King Abdullah Medical City in Holy Capital. The trial plans to enroll 76 participants.